SeaBeLife Secures €2M To Advance Therapies For Liver And Eye Diseases

The round was led by existing investor iXLife with participation from new backers including INEXT and Femmes Business Angels. Funding will support two lead therapeutic programs targeting dry age-related macular degeneration (AMD) and severe acute hepatitis.

SeaBeLife is developing first-in-class small molecules that block both necroptosis and ferroptosis two regulated cell death pathways driving tissue damage in rare, acute, and chronic diseases. This dual-target strategy, currently unavailable on the market, holds transformative potential for organ protection therapies.

“The renewed backing from our longstanding investors, together with the addition of new partners, is a clear signal of confidence in our vision and development strategy, and I am extremely grateful for their support,” said Morgane Rousselot, PhD, CEO and co-founder of SeaBeLife.

“This fundraising is a decisive step towards clinical trials and reinforces our ambition to create a new generation of cutting-edge treatments capable of blocking two major pathways for programmed cell death. We are now actively preparing for a Series A funding round to sustain this momentum.”

Read Also - Austrian Deep Tech Startup Optimuse Raises €4 Million In Seed Funding

SeaBeLife’s leading drug candidates include SBL03 for dry AMD and SBL01 for severe acute hepatitis two areas with high unmet need and few treatment options. The company recently reported positive in vivo data for SBL03 in geographic atrophy, a severe late-stage form of dry AMD.

The round was joined by returning investors Breizh Angels, WeLikeStartup, Angels Santé, and Business Angels des Grandes Ecoles, alongside iXLife and INEXT. Femmes Business Angels, a pan-European women-led investment network, also participated, with Marie-Pierre Sbardella joining SeaBeLife’s Strategic Committee.

To date, SeaBeLife has raised €9 million in equity and public funding, with support from Bpifrance, SATT Ouest Valorisation, Biotech Santé Bretagne, and Région Bretagne. It was also a 2024 winner of the i-Nov Competition, France’s national innovation grant.

While still preclinical SeaBeLife’s dual-pathway inhibition strategy blocking necroptosis and ferroptosis mirrors a broader shift toward multi-target drug development for complex diseases. If successful, its therapies could address patient populations in the millions, representing multi-billion-euro markets.

The company, headquartered in Roscoff and led by a founding team of experts in cellular biology, toxicology, and pharmacology, is now preparing a larger Series A to fund clinical trials and scale its pipeline.

About SeaBeLife

Founded in 2019, SeaBeLife Biotech develops breakthrough small molecules that inhibit regulated necrosis, a key driver in many severe diseases. Focusing on acute and orphan conditions, SeaBeLife advances therapies for acute kidney injury, acute liver failure, neurodegenerative diseases, and AMD, with its lead candidate now in preclinical development.